Mawer Investment Management Ltd. Sells 35,438 Shares of Pathward Financial, Inc. $CASH

Mawer Investment Management Ltd. trimmed its holdings in shares of Pathward Financial, Inc. (NASDAQ:CASH) by 10.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 310,623 shares of the savings and loans company’s stock after selling 35,438 shares during the period. Mawer Investment Management Ltd.’s holdings in Pathward Financial were worth $22,054,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CASH. Allspring Global Investments Holdings LLC boosted its holdings in Pathward Financial by 19.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 159,673 shares of the savings and loans company’s stock worth $11,476,000 after acquiring an additional 26,446 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Pathward Financial by 2,640.8% during the third quarter. Federated Hermes Inc. now owns 25,489 shares of the savings and loans company’s stock valued at $1,886,000 after acquiring an additional 24,559 shares in the last quarter. Aptus Capital Advisors LLC increased its holdings in shares of Pathward Financial by 15.2% during the third quarter. Aptus Capital Advisors LLC now owns 142,215 shares of the savings and loans company’s stock valued at $10,525,000 after acquiring an additional 18,720 shares in the last quarter. Vinva Investment Management Ltd raised its position in shares of Pathward Financial by 24.2% in the 3rd quarter. Vinva Investment Management Ltd now owns 188,804 shares of the savings and loans company’s stock worth $13,973,000 after purchasing an additional 36,781 shares during the last quarter. Finally, Comerica Bank raised its position in shares of Pathward Financial by 371.2% in the 4th quarter. Comerica Bank now owns 295,999 shares of the savings and loans company’s stock worth $21,016,000 after purchasing an additional 233,177 shares during the last quarter. 92.66% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on CASH. Keefe, Bruyette & Woods increased their price objective on shares of Pathward Financial from $100.00 to $108.00 and gave the company an “outperform” rating in a research report on Thursday, April 23rd. Piper Sandler began coverage on shares of Pathward Financial in a report on Thursday, March 12th. They issued an “overweight” rating and a $107.00 target price for the company. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Pathward Financial in a research note on Friday, May 8th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Pathward Financial has a consensus rating of “Buy” and an average target price of $107.50.

Insider Buying and Selling at Pathward Financial

In related news, Director Douglas J. Hajek sold 5,000 shares of Pathward Financial stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $86.37, for a total value of $431,850.00. Following the completion of the sale, the director owned 12,281 shares of the company’s stock, valued at $1,060,709.97. The trade was a 28.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Elizabeth G. Hoople sold 4,500 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.29, for a total value of $370,305.00. Following the sale, the director owned 28,050 shares of the company’s stock, valued at approximately $2,308,234.50. This trade represents a 13.82% decrease in their position. The SEC filing for this sale provides additional information. 1.43% of the stock is owned by corporate insiders.

Pathward Financial Stock Performance

Shares of NASDAQ CASH opened at $80.91 on Tuesday. The firm’s 50-day moving average price is $88.39 and its 200-day moving average price is $83.47. Pathward Financial, Inc. has a 52-week low of $65.87 and a 52-week high of $101.26. The company has a market cap of $1.71 billion, a PE ratio of 9.61 and a beta of 0.64. The company has a quick ratio of 0.80, a current ratio of 0.81 and a debt-to-equity ratio of 0.04.

Pathward Financial (NASDAQ:CASH) last released its quarterly earnings data on Wednesday, April 22nd. The savings and loans company reported $3.35 earnings per share for the quarter, meeting the consensus estimate of $3.35. The firm had revenue of $276.30 million during the quarter, compared to analysts’ expectations of $272.04 million. Pathward Financial had a net margin of 22.42% and a return on equity of 22.35%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $3.11 earnings per share. Pathward Financial has set its FY 2026 guidance at 8.550-9.050 EPS. As a group, analysts anticipate that Pathward Financial, Inc. will post 8.73 EPS for the current year.

Pathward Financial Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Thursday, June 11th will be paid a dividend of $0.05 per share. The ex-dividend date is Thursday, June 11th. This represents a $0.20 dividend on an annualized basis and a yield of 0.2%. Pathward Financial’s payout ratio is currently 2.38%.

About Pathward Financial

Pathward Financial (NASDAQ:CASH) is a U.S.-based financial services company that operates through its wholly owned subsidiary, Pathward Bank. The company provides a range of banking and payment solutions designed for consumers, small businesses, community banks and fintech partners. Core offerings include deposit accounts, consumer and commercial lending, debit and prepaid card programs, digital banking platforms and treasury management services.

Through its banking charter, Pathward Financial delivers customizable payment solutions, including prepaid cards, payroll cards and benefit disbursement programs.